New Approved Treatments for Geographic Atrophy: Insights
With new treatments now approved in Australia, the landscape for geographic atrophy is shifting—offering clinicians and patients new ways to slow disease progression. Find out
With new treatments now approved in Australia, the landscape for geographic atrophy is shifting—offering clinicians and patients new ways to slow disease progression. Find out
Our 6-month interim analysis of the FURGGHORN study, has been published in the latest issue of the Asia-Pacific Journal of Ophthalmology. https://lnkd.in/gRxscBx8. The FURGGHORN study
Kriya Therapeutics announce promising pre-clinical results for KRIYA-825, a single gene therapy delivered via suprachoroidal injection for the treatment of geographic atrophy (GA). KRIYA-825 is
The approval of Eylea 8 mg (aflibercept 8 mg) in China for the treatment of wet age-related macular degeneration (AMD) comes following the positive results
We recently authored an educational article in Mivision Education magazine, explaining target pathways for geographic atrophy (GA) and current therapies under investigation in clinical trials
The recent approval of geographic atrophy (GA) therapy in Australia will significantly change the way eyecare providers manage this irreversible disease. In this educational article,